Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Baxter International Inc (BAX) vs Enovix Corporation (ENVX) Price & Performance

Baxter International IncTrade
Enovix CorporationTrade

Price performance (Past 24H)

Key statistics

Baxter International Inc vs Enovix Corporation — how do they compare? Baxter International Inc trades at $27.61 (market cap $14.36B), while Enovix Corporation trades at $4.9 (market cap $1.01B). The key difference: Baxter International Inc is far larger — about 14.2× Enovix Corporation's market cap, and Baxter International Inc pays a 0.14% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals.

BAXENVX
Market Cap
$14.36B$1.01B
Sector
HealthTechnology
52-Week High
$28.35$13.19
52-Week Low
$15.80$3.68
Enterprise Value
$21.88B$1.03B
Dividend Yield
0.14%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Baxter International Inc

Baxter International (BAX) trades at $27.55, up 2.0% today, showing strong momentum after recent earnings beats. The stock is approaching its 52-week high of $29.35, with technical indicators signaling bullish momentum. Fundamentally, the company reported Q2 2026 earnings of $0.56 per share, beating estimates, and raised full-year guidance, though profitability metrics remain negative with a -9.27% net income margin. Recent news highlights operational improvements and strong demand for IV solutions.

The outlook is cautiously optimistic as Baxter demonstrates turnaround progress with raised guidance and earnings beats. Investment opportunity lies in continued operational execution and margin recovery, but risks include persistent negative profitability, high debt levels, and competitive pressures in the medtech space. Wall Street sentiment is mixed with 42% buy ratings but a consensus price target below current levels.

Enovix Corporation

ENVX trades at $4.70, up 10.33% today, with a bullish technical signal despite negative profitability. Recent earnings beats and a $12.38 consensus price target suggest upside potential. The company is ramping production of advanced silicon-anode batteries, with key developments including a new COO appointment and upcoming Q2 2026 results on August 12, 2026.

Outlook remains speculative with high revenue growth potential but persistent losses; risks include cash burn and competitive pressures. Analyst sentiment is positive (75% buy ratings), but investors should weigh the long-term growth story against near-term financial challenges.

Returns comparison

Trailing returns across standard periods

About Baxter International Inc

Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.

Read more on BAX

About Enovix Corporation

Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.

Read more on ENVX